News coverage about Iradimed (NASDAQ:IRMD) has trended positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Iradimed earned a news impact score of 0.28 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.4319680893128 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research report on Wednesday, February 7th. Credit Suisse Group assumed coverage on shares of Iradimed in a research report on Monday, November 27th. They issued a “buy” rating and a $19.00 price target for the company. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. Iradimed presently has an average rating of “Buy” and a consensus target price of $17.33.
Iradimed (NASDAQ IRMD) traded up $0.22 during midday trading on Wednesday, hitting $13.72. 19,009 shares of the stock were exchanged, compared to its average volume of 18,497. Iradimed has a 52 week low of $7.85 and a 52 week high of $15.85. The firm has a market capitalization of $145.28, a P/E ratio of 274.40 and a beta of 1.55.
Iradimed Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.